Travere Therapeutics, Inc.
TVTX
$28.15
$0.351.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.38% | 301.54% | 69.06% | 31.59% | -9.95% |
| Total Depreciation and Amortization | 14.88% | 12.64% | 9.48% | 5.88% | 7.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -242.73% | 8.49% | -5.67% | 198.26% | -57.36% |
| Change in Net Operating Assets | 241.07% | -562.15% | 76.20% | -420.13% | 209.84% |
| Cash from Operations | 323.82% | 187.32% | 111.81% | -18.12% | 15.97% |
| Capital Expenditure | 367.86% | 40.43% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -221.31% | 1,605.62% | -87.68% | 151.36% | -274.29% |
| Cash from Investing | -221.07% | 1,685.38% | -88.25% | 151.41% | -274.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 565.13% | 104.50% | -52.86% | -96.96% | 24,356.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 140.83% | -4,529.76% | -60.33% | -97.33% | 302,332.61% |
| Foreign Exchange rate Adjustments | -299.52% | -89.38% | 255.66% | 156.85% | -312.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.02% | 169.86% | 294.32% | -84.81% | 437.30% |